4D Pharma Presents Results of MRx-4DP0004 in P-I/II Trial for the Treatment of Asthma at ATS 2022
Shots:
- The company reported the results from part A of the P-I/II trial to evaluate MRx-4DP0004 vs PBO in patients with asthma
- The results showed that a greater proportion of patients experienced an 83.3% vs 56.3% reduction in ACQ-6 scores at end of treatment, 50% vs 18.8% reduced the use of SABA rescue medication & 50% vs 31.3% experienced an improvement in AQLQ scores of ≥0.5 from baseline at the end of the treatment period (day 85)
- Additionally, mean measures of lung function remained stable from baseline and throughout the treatment period, was safe and well-tolerated with no TRAEs or serious AEs. The company continues to advance the therapy & plans to enroll patients in part B of the P-I/II trial, based on the part A results
Ref: 4dpharmaplc | Image: 4D Pharma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
